Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 2/20 | 0.63 |
| ▸ | RAD1 | O60671 | 1/20 | 0.63 |
| ▸ | RAD51 | Q06609 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 2/20 | 0.48 |
| ▸ | LTA | P01374 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | SENP2 | Q9HC62 | 5/20 | 0.41 |
| ▸ | SENP1 | Q9P0U3 | 5/20 | 0.41 |
| ▸ | SENP3 | Q9H4L4 | 4/20 | 0.41 |
| ▸ | SUMO2 | P61956 | 3/20 | 0.41 |
| ▸ | SUMO1 | P63165 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30727492 | 1.00 | P2RY6 (0.63) | P2RY6RAD1RAD51MAPTCYP3A4 | |
| Acridine SCHEMBL5792145 | 0.92 | RAD1 (0.53) | P2RY6RAD1RAD51MAPTCYP3A4 | |
| Acridine SCHEMBL6039596 | 0.92 | RAD1 (0.53) | P2RY6RAD1RAD51MAPTCYP3A4 | |
| SCHEMBL31475554 | 0.85 | RAD51 (0.60) | P2RY6RAD1RAD51MAPTCYP3A4 | |
| SCHEMBL25796 | 0.83 | RAD51 (0.81) | P2RY6RAD1RAD51MAPTCYP3A4 | |
| SCHEMBL29351606 | 0.83 | RAD51 (0.81) | P2RY6RAD1RAD51MAPTCYP3A4 | |
| SCHEMBL175934 | 0.83 | RAD51 (0.81) | P2RY6RAD1RAD51MAPTCYP3A4 | |
| SCHEMBL2333703 | 0.82 | RAD51 (0.80) | P2RY6RAD1RAD51MAPTCYP3A4 | |
| SCHEMBL15823509 | 0.82 | RAD51 (0.80) | P2RY6RAD1RAD51MAPTCYP3A4 | |
| SCHEMBL30160852 | 0.82 | RAD51 (0.80) | P2RY6RAD1RAD51MAPTCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4396581-A1 | MULTIPLEXED PROTEOMICS ANALYSIS USING OLIGONUCLEOTIDE-CONJUGATED ANTIBODIES | Becton, Dickinson and Company (US) | 2024-07-10 | — | — | EP | disclosed |
| WO-2023114231-A1 | CLUSTERED MUTATIONS FOR THE TREATMENT OF CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023034789-A1 | MULTIPLEXED PROTEOMICS ANALYSIS USING OLIGONUCLEOTIDE-CONJUGATED ANTIBODIES | BECTON, DICKINSON AND COMPANY (US) | 2023-03-09 | — | — | WO | disclosed |
| WO-2016018562-A1 | GENERATION AND USE OF POLYCLONAL AND MONOCLONAL ANTIBODIES SPECIFIC FOR 3-PHOSPHOHISTIDINE | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2016-02-04 | — | — | WO | disclosed |
| EP-2147110-A2 | NOVEL SIMIAN T-CELL LYMPHOTROPIC VIRUS | The Gov. Of The USA As Represented By The Secretary Of The Dept. Of Health & Human Services (US) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008144700-A2 | SIMIAN T-CELL LYMPHOTROPIC VIRUS TYPE 3 WEST AFRICAN SUBTYPE D | THE GOV. OF THE USA AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH & HUMAN SERVICES (US) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008131191-A2 | NUCLEIC ACIDS HYBRIDIZABLE TO MICRO RNA AND PRECURSORS THEREOF | AMGEN INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| EP-1492800-A2 | PROCESS FOR MANUFACTURING PURIFIED PHOSPHORODIAMIDITE | ISIS PHARMACEUTICALS, INC. (US) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003087130-A2 | PROCESS FOR MANUFACTURING PURIFIED PHOSPHORODIAMIDITE | ISIS PHARMACEUTICALS, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| WO-2003048378-A2 | METHODS AND COMPOSITIONS FOR SELECTIVELY CLEAVING DNA CONTAINING DUPLEX ACIDS IN A COMPLEX NUCLEIC ACID MIXTURE | EUREGEN LLC (US) | 2003-06-12 | — | — | WO | disclosed |
| WO-2002068672-A3 | ANTISENSE MODULATION OF RECQL4 EXPRESSION | ISIS PHARMACEUTICALS INC (US) | 2002-10-17 | — | — | WO | disclosed |
| WO-2002055659-A2 | ANTISENSE MODULATION OF INTEGRIN BETA 4 BINDING PROTEIN EXPRESSION | ISIS PHARMACEUTICALS INC (US) | 2002-07-18 | — | — | WO | disclosed |